Bayer moves closer to another Eylea filing after Regeneron raises sales projections
This article was originally published in Scrip
Top-line results have been presented of the eye drug Eylea (aflibercept; also known as VEGF Trap-Eye) after one year of treatment in the Phase III GALILEO study in patients with macular oedema due to central retinal vein occlusion (CRVO). Based on the results of this study and one other, Regeneron Pharmaceuticals, Eylea's originator, has submitted a supplemental Biologics License Application (sBLA) in the US for the CRVO indication and has been granted an FDA action date of 23 September 2012. The latest data confirm the primary endpoint results that were seen after 24 weeks from two pivotal trials, GALILEO and COPERNICUS. The results are also in line with previously reported one-year results from the COPERNICUS study.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.